Current Report · Items 7.01, 9.01 · 8-K

TransCode Therapeutics, Inc.

RNAZNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Jun 18, 2026Accepted Jun 18, 2026, 8:00 AM EDTCIK 1829635Accession 0001104659-26-075440

Company context

TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.

Current securities

RNAZNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Press Release On June 18, 2026, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”) posted a presentation to its website that may be used by the Company from time to time with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including the information in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act of 1933, as amended.

Filed exhibits (1)

EX-99.1 (by filename) tm2618153d1_ex99-1.htm

EX-99.1 2 tm2618153d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Three Platforms, One Mission: Transforming Advanced Cancer Care NASDAQ: RNAZ Company Forward Looking Statement 2 Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings with the U.S. Securities and Exchange Commission (“SEC”) for more complete information about the Company. You can obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company will send you these documents at no charge if you request them from TransCode at 6 Liberty Square, #2382, Boston, MA 02109, Attention: Investor Relations; or by calling (857) 837-3099. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall TransCode make any sale of its securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Statements in this presentation contain “forward-looking statements” that are subject to substant…

Open exhibit ↗